SCHEMBL5681194

SCHEMBL5681194

CC1CC(=O)NN=C1c1ccc(/C(=N/N)c2ccccc2C(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ PDE3B Q13370 12/20 0.50
▸ PDE3A Q14432 12/20 0.50
▸ GPR119 Q8TDV5 4/20 0.46
▸ TNNC1 P63316 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ PDE4A P27815 2/20 0.43
▸ PDE4B Q07343 2/20 0.43
▸ PDE4C Q08493 2/20 0.43
▸ PDE4D Q08499 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5681207 1.00 SMN1; SMN2 (0.51) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL5677114 0.83 PDE3B (0.46) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL6496001 0.80 PDE3B (0.65) SMN1; SMN2MAPTPDE3BPDE3ATNNC1
SCHEMBL5679287 0.78 PDE3B (0.55) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL5679278 0.78 PDE3B (0.55) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL4414285 0.76 PDE3B (0.64) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL7296342 0.76 PDE3B (0.61) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL16157002 0.76 PDE3B (0.61) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL5681464 0.76 GPR119 (0.53) SMN1; SMN2MAPTPDE3BPDE3AGPR119
SCHEMBL5679329 0.75 PDE3B (0.51) SMN1; SMN2MAPTPDE3BPDE3AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265871-B1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORP (FI) 2006-02-08 — — EP disclosed
US-6699868-B2 INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE ORION CORPORATION (FI) 2004-03-02 — — US disclosed
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure ORION CORPORATION (FI) 2003-08-21 — — US disclosed
EP-1265871-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2002-12-18 — — EP disclosed
WO-2001068611-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure FABP3, TNNI3, TNNT2 SMN1; SMN2 3452/4885MAPT 4871/4885PDE3B 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback